Publications
- 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group2013 | Central Library of Charles University
- Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial +12012 | First Faculty of Medicine
- 2.3.1. Erythropoetin2012 | First Faculty of Medicine
- 2.3.2. G-CSF, Growth factor for granulocytic series2012 | First Faculty of Medicine
- Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study2011 | First Faculty of Medicine
- Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy2010 | First Faculty of Medicine
- Molecular cytogenetic study of immunofluorescently labeled plasma cells in patients with multiple myeloma enrolled in study CMG 20022008 | First Faculty of Medicine
- Autologous transplantation in 495 multiple myeloma patients - Analysis from the Czech National Registry of Hematopoietic Stem Cell Transplantation2007 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Gain/amplification of 1q21 is the most powerful genetic prognostic factor for patients treated by autologous stem cell transplantationPublication without faculty affiliation
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
Loading network view...